Ignite Creation Date:
2025-12-24 @ 3:25 PM
Ignite Modification Date:
2026-01-03 @ 9:12 AM
Study NCT ID:
NCT04148092
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2020-05-29
First Post:
2019-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
Sponsor:
Deciphera Pharmaceuticals, LLC
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
DCC-2618-99-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None